RGLS logo

Regulus Therapeutics (RGLS) Cash From Operations

Annual CFO

-$26.77 M
-$1.24 M-4.87%

December 31, 2023


Summary


Performance

RGLS Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRGLScash flowmetrics:

Quarterly CFO

-$9.45 M
+$2.19 M+18.80%

September 30, 2024


Summary


Performance

RGLS Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRGLScash flowmetrics:

TTM CFO

-$35.95 M
-$3.17 M-9.68%

September 30, 2024


Summary


Performance

RGLS TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRGLScash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

RGLS Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-4.9%+18.8%-9.7%
3 y3 years-113.5%-53.4%-38.6%
5 y5 years+38.1%-100.2%-193.6%

RGLS Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-10.9%at low-54.3%+18.8%-49.0%at low
5 y5-year-113.5%at low-396.3%+18.8%-198.5%at low
alltimeall time-317.5%+54.5%-396.3%+49.4%-601.1%+46.0%

Regulus Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
-$9.45 M(-18.8%)
-$35.95 M(+9.7%)
Jun 2024
-
-$11.64 M(+33.1%)
-$32.78 M(+19.7%)
Mar 2024
-
-$8.74 M(+42.7%)
-$27.40 M(+2.3%)
Dec 2023
-$26.77 M(+4.9%)
-$6.13 M(-2.4%)
-$26.77 M(-0.5%)
Sep 2023
-
-$6.28 M(+0.4%)
-$26.90 M(-1.7%)
Jun 2023
-
-$6.25 M(-22.9%)
-$27.35 M(+0.3%)
Mar 2023
-
-$8.11 M(+29.8%)
-$27.26 M(+6.8%)
Dec 2022
-$25.53 M(+5.8%)
-$6.25 M(-7.1%)
-$25.53 M(-5.8%)
Sep 2022
-
-$6.73 M(+9.3%)
-$27.10 M(+4.5%)
Jun 2022
-
-$6.16 M(-3.5%)
-$25.93 M(+4.6%)
Mar 2022
-
-$6.38 M(-18.5%)
-$24.80 M(+2.8%)
Dec 2021
-$24.13 M(+92.5%)
-$7.83 M(+40.8%)
-$24.13 M(+84.1%)
Sep 2021
-
-$5.56 M(+10.7%)
-$13.11 M(+8.8%)
Jun 2021
-
-$5.02 M(-12.0%)
-$12.04 M(-1.6%)
Mar 2021
-
-$5.71 M(-279.1%)
-$12.24 M(-2.3%)
Dec 2020
-$12.54 M(-36.8%)
$3.19 M(-170.9%)
-$12.54 M(-39.4%)
Sep 2020
-
-$4.50 M(-13.9%)
-$20.70 M(-1.1%)
Jun 2020
-
-$5.23 M(-12.9%)
-$20.93 M(-2.2%)
Mar 2020
-
-$6.00 M(+20.6%)
-$21.39 M(+7.9%)
Dec 2019
-$19.82 M(-54.2%)
-$4.98 M(+5.4%)
-$19.82 M(+5.1%)
Sep 2019
-
-$4.72 M(-17.1%)
-$18.86 M(-26.3%)
Jun 2019
-
-$5.69 M(+28.4%)
-$25.59 M(-20.3%)
Mar 2019
-
-$4.43 M(+10.4%)
-$32.10 M(-25.8%)
Dec 2018
-$43.27 M
-$4.02 M(-64.9%)
-$43.27 M(-14.1%)
Sep 2018
-
-$11.45 M(-6.3%)
-$50.36 M(-0.4%)
Jun 2018
-
-$12.21 M(-21.7%)
-$50.58 M(-9.2%)
DateAnnualQuarterlyTTM
Mar 2018
-
-$15.60 M(+40.5%)
-$55.70 M(-5.2%)
Dec 2017
-$58.77 M(+3.3%)
-$11.10 M(-4.8%)
-$58.77 M(-6.4%)
Sep 2017
-
-$11.66 M(-32.7%)
-$62.78 M(-5.8%)
Jun 2017
-
-$17.33 M(-7.2%)
-$66.61 M(-0.0%)
Mar 2017
-
-$18.68 M(+23.7%)
-$66.63 M(+17.1%)
Dec 2016
-$56.88 M(+14.1%)
-$15.11 M(-2.5%)
-$56.88 M(-3.3%)
Sep 2016
-
-$15.50 M(-10.6%)
-$58.82 M(+6.7%)
Jun 2016
-
-$17.34 M(+94.2%)
-$55.12 M(+15.9%)
Mar 2016
-
-$8.93 M(-47.6%)
-$47.54 M(-4.7%)
Dec 2015
-$49.86 M(+26.2%)
-$17.04 M(+44.4%)
-$49.86 M(+12.1%)
Sep 2015
-
-$11.80 M(+20.9%)
-$44.47 M(+7.2%)
Jun 2015
-
-$9.76 M(-13.2%)
-$41.47 M(-0.6%)
Mar 2015
-
-$11.25 M(-3.5%)
-$41.73 M(+5.6%)
Dec 2014
-$39.51 M(+39.5%)
-$11.66 M(+32.4%)
-$39.51 M(+6.3%)
Sep 2014
-
-$8.80 M(-12.2%)
-$37.17 M(+13.3%)
Jun 2014
-
-$10.02 M(+11.0%)
-$32.79 M(+8.6%)
Mar 2014
-
-$9.03 M(-3.1%)
-$30.20 M(+6.6%)
Dec 2013
-$28.33 M(+224.8%)
-$9.31 M(+110.3%)
-$28.33 M(+56.0%)
Sep 2013
-
-$4.43 M(-40.4%)
-$18.16 M(+34.4%)
Jun 2013
-
-$7.43 M(+3.9%)
-$13.51 M(+25.7%)
Mar 2013
-
-$7.16 M(-940.8%)
-$10.75 M(+23.2%)
Dec 2012
-$8.72 M(-42.1%)
$851.00 K(+278.2%)
-$8.72 M(-8.9%)
Sep 2012
-
$225.00 K(-104.8%)
-$9.57 M(-2.3%)
Jun 2012
-
-$4.67 M(-9.0%)
-$9.80 M(+91.0%)
Mar 2012
-
-$5.13 M
-$5.13 M
Dec 2011
-$15.06 M(-222.4%)
-
-
Dec 2010
$12.31 M
-
-

FAQ

  • What is Regulus Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Regulus Therapeutics?
  • What is Regulus Therapeutics annual CFO year-on-year change?
  • What is Regulus Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Regulus Therapeutics?
  • What is Regulus Therapeutics quarterly CFO year-on-year change?
  • What is Regulus Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Regulus Therapeutics?
  • What is Regulus Therapeutics TTM CFO year-on-year change?

What is Regulus Therapeutics annual cash flow from operations?

The current annual CFO of RGLS is -$26.77 M

What is the all time high annual CFO for Regulus Therapeutics?

Regulus Therapeutics all-time high annual cash flow from operations is $12.31 M

What is Regulus Therapeutics annual CFO year-on-year change?

Over the past year, RGLS annual cash flow from operations has changed by -$1.24 M (-4.87%)

What is Regulus Therapeutics quarterly cash flow from operations?

The current quarterly CFO of RGLS is -$9.45 M

What is the all time high quarterly CFO for Regulus Therapeutics?

Regulus Therapeutics all-time high quarterly cash flow from operations is $3.19 M

What is Regulus Therapeutics quarterly CFO year-on-year change?

Over the past year, RGLS quarterly cash flow from operations has changed by +$2.19 M (+18.80%)

What is Regulus Therapeutics TTM cash flow from operations?

The current TTM CFO of RGLS is -$35.95 M

What is the all time high TTM CFO for Regulus Therapeutics?

Regulus Therapeutics all-time high TTM cash flow from operations is -$5.13 M

What is Regulus Therapeutics TTM CFO year-on-year change?

Over the past year, RGLS TTM cash flow from operations has changed by -$3.17 M (-9.68%)